dostęp otwarty
Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage
dostęp otwarty
Streszczenie
Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.
This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.
Streszczenie
Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.
This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.
Słowa kluczowe
cardiotoxicity, molecular target therapy, arterial hypertension, cardiac failure, arrhythmias, drug side-effects
Informacje o artykuleTytuł
Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage
Czasopismo
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory
Numer
Strony
34-40
Opublikowany online
2017-08-25
Wyświetlenia strony
295
Wyświetlenia/pobrania artykułu
346
Rekord bibliograficzny
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2017;2(1):34-40.
Słowa kluczowe
cardiotoxicity
molecular target therapy
arterial hypertension
cardiac failure
arrhythmias
drug side-effects
Autorzy
Beata Jagielska
Konrad Tałasiewicz
Aleksandra Czachowska
Katarzyna Gepner
Elżbieta Mądro
Małgorzata Symonides
Paweł Wiechno
Maciej Krzakowski
